Almotriptan for the treatment of acute migraine: A review of early intervention trials

Expert Review of Neurotherapeutics

Volumn 10, Issue 3, 2010, Pages 351-364

  Antonaci, Fabio ^a   De Cillis, Ilaria ^a   Cuzzoni, Maria Giovanna ^b   Allena, Marta ^c  

^a Polyclinic of Monza   (Italy)

^b University Centre for Adaptive Disorders and Headache UCADH   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Allodynia; Almotriptan; Early treatment; Migraine

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; ERGOTAMINE; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ALLODYNIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; MIGRAINE; NAUSEA; PHONOPHOBIA; PHOTOPHOBIA; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; SYMPTOM; THORAX PAIN; TREATMENT OUTCOME;

ACUTE DISEASE; CLINICAL TRIALS AS TOPIC; DISABILITY EVALUATION; HUMANS; MIGRAINE DISORDERS; PAIN MEASUREMENT; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 77649324522     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.160     Document Type: Review

References (58)

1. World Health Organization. The Global Burden of Disease: 2004 Update. WHO, Geneva, Switzerland (2004).
2. International Headache Society. The International Classification of Headache Disorders (Second Edition). Blackwell Publishing, Oxford, UK (2005).
3. 1B/1D receptor agonists. Arch. Neurol. 59(7), 1084-1088 (2002).
4. Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur. J. Neurol. 12(Suppl. 1), 1-27 (2005).
5. Tfelt-Hansen P, Saxena PR, Dahlöf C et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 123 (Pt 1), 9-18 (2000).
6. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294), 1668-1675 (2001).
7. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22(8), 633-658 (2002).
8. Erratum in: Cephalalgia 23, 71 (2003).
9. Tfelt-Hansen P, Block G, Dahlöf C et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 20(9), 765-786 (2000).
10. Gendolla A. Early treatment in migraine: how strong is the current evidence? Cephalalgia 28(Suppl. 2), 28-35 (2008).
11. Freitag FG, Finlayson G, Rapoport AM et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). Headache 47(4), 519-530 (2007).
12. Goadsby PJ, Zanchin G, Geraud G et al. Early vs. non-early intervention in acute migraine - 'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 28(4), 383-391 (2008).
13. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 43(1), 36-43 (2003).
14. Edmeads J. Understanding the needs of migraine patients. Drugs 66(Suppl. 3), 1-8 (2006).
15. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann. Neurol. 47(5), 614-624 (2000).
16. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol. 55(1), 19-26 (2004).
17. Pryse-Phillips W, Aubé M, Bailey P et al. A clinical study of migraine evolution. Headache 46(10), 1480-1486 (2006).
18. Gras J. Almotriptan, a new anti-migraine agent: a review. CNS Drug Rev. 8, 217-234 (2002).
19. Láinez MJ. Almotriptan: meeting today's needs in acute migraine treatment. Expert Rev. Neurother. 7(12), 1659-1673 (2007).
20. Dahlöf CG, Pascual J, Dodick DW, Dowson AJ. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia 26(4), 400-408 (2006).
21. Mathew NT. Almotriptan increases pain-free status in patients with acute migraine treated in placebo-controlled clinical trials. Headache 42(Suppl. 1), 32-37 (2002).
22. Cady R. Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis. Headache 42(Suppl. 1), 26-31 (2002).
23. Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache 41(5), 449-455 (2001).
24. Mathew NT; for the Oral Almotriptan Study Group. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine. Headache 42(1), 32-40 (2002).
25. Pascual J, Falk R, Docekal R et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur. Neurol. 45(4), 206-213 (2001).
26. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J. Postgrad. Med. 48(3), 206-208 (2002).
27. Antonaci F, Chimento P, Diener HC, Sances G, Bono G. Lessons from placebo effects in migraine treatment. J. Headache Pain 8(1), 63-66 (2007).
28. Solomon S. A review of mechanisms of response to pain therapy: why voodoo works. Headache 42(7), 656-662 (2002).
29. Dodick DW. Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials. Headache 42(1), 21-27 (2002).
30. Dodick DW, Sandrini G, Williams P. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs 21(1), 73-82 (2007).
31. Láinez MJ, Galván J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur. J. Neurol. 14(3), 269-275 (2007).
32. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 42(1), 28-31 (2002).
33. Mathew NT. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 43(10), 1075-1079 (2003).
34. Sandrini G, Dahlöf CG, Mathew N, Nappi G. Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine. Int. J. Clin. Pract. 59(11), 1356-1365 (2005).
35. Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan improves response rates when treatment is within | 1 hour of migraine onset. Headache 44(4), 318-322 (2004).
36. Dowson AJ, Massiou H, Laínez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia 22(6), 453-461 (2002).
37. Pascual J, Láinez JM, Leira R et al. [Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study]. Neurologia 18(1), 7-17 (2003).
38. Pascual J, Tranche S, Leira R, Lainez JM, Mateos V, Galvan J. Almotriptan in clinical practice: experience in a primary care vs neurology setting. Headache 43, 525 (2003).
39. Láinez MJ, Pascual J, Mateos V, Galvan J. Real world experience comparing neurologists and primary care physician management of acute migraine with almotriptan in Spain. Presented at: 56th Annual Meeting of the American Academy of Neurology. San Francisco, CA, USA, 24 April-1 May 2004.
40. Mathew NT, Finlayson G, Smith TR et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT® Early Migraine Intervention Study). Headache 47(2), 189-198 (2007).
41. Freitag F, Smith T, Mathew N et al. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. Headache 48(3), 341-354 (2008).
42. Lantéri-Minet M, Allaf B, Mick G. Right triptan use in clinical conditions: results of TEMPO study. Neurology 66(5 Suppl. 2), A43 (2006).
43. Díaz-Insa S, Goadsby PJ, Zanchin G et al. Early treatment with almotriptan allows a good outcome even in allodynic migraine patients. An Act when Mild (AwM) substudy. Presented at: European Headache and Migraine Trust International Congress. London, UK, 4-7 September 2008 (Poster PC 02).
44. Schoenen J, De Klippel N, Giurgea S et al. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia 28(10), 1095-1105 (2008).
45. Cady R, Martin V, Mauskop A et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia 27(9), 1055-1060 (2007).
46. Janknegt R, Steenhoek A. The System of Objectified Judgement Analysis (SOJA). A tool in rational drug selection for formulary inclusion. Drugs 53(4), 550-562 (1997).
47. Janknegt R. Triptans in the treatment of migraine: drug selection by means of the SOJA method. Expert Opin. Pharmacother. 8(Suppl. 1), S15-S30 (2007).
48. Goadsby PJ, Dodick DW, Ferrari MD, McCrory DC, Williams P. TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. Acta Neurol. Scand. 110(3), 137-143 (2004).
49. Kaniecki R. Headache assessment and management. JAMA 289(11), 1430-1433 (2003).
50. Dodick DW. Applying the benefits of the AwM study in the clinic. Cephalalgia 28(Suppl. 2), 42-49 (2008).
51. De Klippel N, Jansen JP, Carlos JS. Survey to evaluate diagnosis and management of headache in primary care: Headache Management Pattern programme. Curr. Med. Res. Opin. 24(12), 3413-3422 (2008).
52. Foley KA, Cady R, Martin V et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache 45(5), 538-545 (2005).
53. Ng-Mak DS, Cady R, Chen YT, Ma L, Bell CF, Hu XH. Can migraineurs accurately identify their headaches as "migraine" at attack onset? Headache 47(5), 645-653 (2007).
54. Kelman L, Von Seggern RL. Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy. Am. J. Ther. 13(5), 411-417 (2006).
55. Williams P, Reeder CE. A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J. Manag. Care Pharm. 10(3), 259-265 (2004).
56. Gori S, Morelli N, Acuto G, Caiola F, Iudice A, Murri L. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy. Minerva Med. 97(6), 467-477 (2006).
57. Freitag F. Pharmacoeconomic benefits of almotriptan in the acute treatment of migraine. Expert Rev. Pharmacoecenomics Outcomes Res. 8(2), 105-110 (2008).
58. Slof J, Láinez J, Comas A, Heras J. Almotriptan vs. ergotamine plus caffeine for acute migraine treatment. A cost-efficacy analysis. Neurologia 24, 147-153 (2009).